SlideShare a Scribd company logo
1 of 1
Download to read offline
Combined Esophagogastrectomies: Survival Outcomes
in Patients with Local Advanced Esophageal Cancer
Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
OBJECTIVE: The survival of patients with local advanced of esophageal cancer (EC) takes several months. Radical
operations are extremely complex and remain the prerogative of several best thoracoabdominal surgeons of the
world. The search of optimal treatment plan for EC patients (ECP) with stage T4N0-2M0 was realized. We examined
factors in terms of precise prediction of 5-year survival (5YS) of local advanced ECP after complete (R0) combined
esophagogastrectomies (E).
METHODS: We analyzed data of 153 consecutive ECP (age=54.9±9. years; tumor size=7.8±2.5 cm) radically operated
and monitored in 1975-2020 (m=118, f=35; Lewis=48, Garlock=105, combined E with resection of trachea, bronchus,
lung, aorta, VCS, pericardium, liver, pancreas, diaphragm, colon, splenectomy=153; only surgery-S=99, adjuvant
chemoimmunoradiotherapy-AT=54: 5FU+thymalin/taktivin +radiotherapy 45-50Gy; T4=153; N0=56, N1=17, N2=80,
M0=153; G1=32, G2=23, G3=98; squamous=54, adenocarcinoma=97, mix=2. Variables selected for 5YS study were
input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the
Kaplan-Meier method. Differences in curves between groups of ECP were evaluated using a log-rank test. Multivariate
Cox modeling, multi-factor clustering, discriminant analysis, structural equation modeling, Monte Carlo, bootstrap
simulation and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1518.3±1945.4 days and cumulative 5YS reached 38.9%, 10 years – 26.8%, 20
years – 19.8%. 40 ECP lived more than 5 years (LS=4030.5±2386.8 days), 14 – more than 10 years (LS=6674±2258.5
days). 79 ECP died because of EC (LS=632.3±309.1 days). AT significantly improved 5YS (51.1% vs. 33.9%), AT, age,
blood cells, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), ESS, prothrombin index,
protein (P=0.000-0.040). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships
between 5YS and N0-12 (rank=1), eosinophils/CC (rank=2), stick neutrophils/CC (3), healthy cells/CC (4),
erythrocytes/CC (5), monocytes/CC (6), lymphocytes/CC (7), thrombocytes/CC (8), segmented neutrophils/CC (9),
leucocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing.
CONCLUSIONS: 5YS of local advanced ECP after combined radical procedures significantly depended on: tumor
characteristics, blood cell circuit, cell ratio factors, biochemical factors, hemostasis system, anthropometric data and
adjuvant treatment. Optimal strategies for local advanced ECP are: 1) availability of very experienced
thoracoabdominal surgeons because of complexity radical procedures; 2) aggressive en block
surgery and adequate lymph node dissection for completeness; 3) precise prediction;
4) AT for ECP with unfavorable prognosis.
Neural Networks:
Baseline Error=0.000; Area under
ROC Curve=1.000; Correct
Classification Rate=100%; n=119
Rank Sensitivity
Phase Transition N0---N12 1 701
Eosinophils/Cancer Cells 2 491
Stick Neutrophils/Cancer Cells 3 269
Healthy Cells/Cancer Cells 4 176
Erythrocytes/Cancer Cells 5 175
Monocytes/Cancer Cells 6 151
Lymphocytes/Cancer Cells 7 124
Thrombocytes/Cancer Cells 8 100
Segmented Neutrophils/Cancer Cells 9 30
Leucocytes/Cancer Cells 10 24
Cox Proportional Hazards Results,
ECPT4N0-2M0, n=153
Parameter
Estimate
Standard
Error
Chi2 P value
Leucocytes -14.7695 3.568331 17.13163 0.000035
Monocytes (%) 0.9933 0.194297 26.13352 0.000000
ESS -0.0462 0.016035 8.29704 0.003971
Prothrombin Index 0.0745 0.016092 21.43087 0.000004
Eosinophils (abs) 24.0232 5.699437 17.76637 0.000025
Stick Neutrophils (abs) 11.5798 2.880807 16.15746 0.000058
Segmented Neutrophils (abs) 14.1418 3.858441 13.43337 0.000247
Lymphocytes (abs) 18.2601 4.034686 20.48277 0.000006
Phase Transition N0---N12 1.7942 0.350778 26.16159 0.000000
Age 0.0607 0.014796 16.81244 0.000041
Histology -0.9610 0.299217 10.31426 0.001320
Tumor Growth -0.7728 0.333794 5.36023 0.020601
Stick Neutrophils/Cancer Cells -10.4603 3.448870 9.19888 0.002422
Monocytes/Cancer Cells -11.4366 4.369661 6.85007 0.008864
Esophageal/Cardioesophageal Cancer 1.1047 0.305000 13.11926 0.000292
Eosinophils (%) -0.8866 0.224724 15.56375 0.000080
Segmented Neutrophils/Cancer Cells 1.2604 0.487956 6.67204 0.009794
Lymphocytes (tot) -2.7854 0.649292 18.40364 0.000018
Segmented Neutrophils (tot) -2.0776 0.573809 13.10942 0.000294
Leucocytes (tot) 2.1281 0.517175 16.93226 0.000039
Adjuvant Chemoimmunotherapy -1.4382 0.359631 15.99294 0.000064
G1-3 0.4878 0.167933 8.43792 0.003675
Protein 0.0438 0.019390 5.11383 0.023736
Healthy Cells/Cancer Cells 0.4984 0.231522 4.63402 0.031344
Erythrocytes/Cancer Cells -1.4656 0.604416 5.87966 0.015317
Thrombocytes/Cancer Cells -0.0114 0.005583 4.17846 0.040941
Eosinophils/Cancer Cells -10.6284 4.948386 4.61329 0.031725
Bootstrap Simulation:
Number of Samples=3333
Rank Kendall
Tau
P<
Hemorrhage Time 1 -0.171 0.05
Blood Chlorides 2 0.171 0.05
Esophageal/Cardioesophageal
Cancer 3 -0.151 0.05
Prothrombin Index 4 -0.146 0.05
Phase Transition N0---N12 5 -0.144 0.05
Protein 6 -0.142 0.05
Survival Function
5-Year Survival=38.9%; 10-Year Survival=26.8%; 20-Year Survival=19.8%;
n=153; T4N0-2M0
Complete Censored
-5 0 5 10 15 20 25 30 35
Years after Combined Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of ECP with N0=52.8%; 5-Year Survival of ECP with N1-2=29.2%;
P=0.00072 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30
Years after Combined Esophagogastrectomies
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival after AT=51.1%; 5-Year Survival after Surgery=33.9%;
P=0.007 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Combined Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
only Surgery=99
AT=54
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of ECP=58.3%; 5-Year Survival of CECP=29.4%;
P=0.00007 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Combined Esophagogastrectomies
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
ECP=58
CECP=105

More Related Content

What's hot

Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsOleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionOleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Oleg Kshivets
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017Oleg Kshivets
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Oleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021Oleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015Oleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer SurgeryOleg Kshivets
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Oleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Oleg Kshivets
 

What's hot (20)

Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 

Similar to Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Advanced Esophageal Cancer

Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaOleg Kshivets
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Oleg Kshivets
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019Oleg Kshivets
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival Oleg Kshivets
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018Oleg Kshivets
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016Oleg Kshivets
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017Oleg Kshivets
 
Medullary carcinoma of thyroid genene m. bekele, md, face
Medullary carcinoma of thyroid   genene m. bekele, md, faceMedullary carcinoma of thyroid   genene m. bekele, md, face
Medullary carcinoma of thyroid genene m. bekele, md, faceGofasefer
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrOleg Kshivets
 

Similar to Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Advanced Esophageal Cancer (20)

Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Medullary carcinoma of thyroid genene m. bekele, md, face
Medullary carcinoma of thyroid   genene m. bekele, md, faceMedullary carcinoma of thyroid   genene m. bekele, md, face
Medullary carcinoma of thyroid genene m. bekele, md, face
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 

More from Oleg Kshivets

Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfOleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfOleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise PredictionOleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 

More from Oleg Kshivets (13)

Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets IASLC 2019
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
 

Recently uploaded

The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 

Recently uploaded (20)

The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 

Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Advanced Esophageal Cancer

  • 1. Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Advanced Esophageal Cancer Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia OBJECTIVE: The survival of patients with local advanced of esophageal cancer (EC) takes several months. Radical operations are extremely complex and remain the prerogative of several best thoracoabdominal surgeons of the world. The search of optimal treatment plan for EC patients (ECP) with stage T4N0-2M0 was realized. We examined factors in terms of precise prediction of 5-year survival (5YS) of local advanced ECP after complete (R0) combined esophagogastrectomies (E). METHODS: We analyzed data of 153 consecutive ECP (age=54.9±9. years; tumor size=7.8±2.5 cm) radically operated and monitored in 1975-2020 (m=118, f=35; Lewis=48, Garlock=105, combined E with resection of trachea, bronchus, lung, aorta, VCS, pericardium, liver, pancreas, diaphragm, colon, splenectomy=153; only surgery-S=99, adjuvant chemoimmunoradiotherapy-AT=54: 5FU+thymalin/taktivin +radiotherapy 45-50Gy; T4=153; N0=56, N1=17, N2=80, M0=153; G1=32, G2=23, G3=98; squamous=54, adenocarcinoma=97, mix=2. Variables selected for 5YS study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of ECP were evaluated using a log-rank test. Multivariate Cox modeling, multi-factor clustering, discriminant analysis, structural equation modeling, Monte Carlo, bootstrap simulation and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1518.3±1945.4 days and cumulative 5YS reached 38.9%, 10 years – 26.8%, 20 years – 19.8%. 40 ECP lived more than 5 years (LS=4030.5±2386.8 days), 14 – more than 10 years (LS=6674±2258.5 days). 79 ECP died because of EC (LS=632.3±309.1 days). AT significantly improved 5YS (51.1% vs. 33.9%), AT, age, blood cells, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), ESS, prothrombin index, protein (P=0.000-0.040). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), eosinophils/CC (rank=2), stick neutrophils/CC (3), healthy cells/CC (4), erythrocytes/CC (5), monocytes/CC (6), lymphocytes/CC (7), thrombocytes/CC (8), segmented neutrophils/CC (9), leucocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: 5YS of local advanced ECP after combined radical procedures significantly depended on: tumor characteristics, blood cell circuit, cell ratio factors, biochemical factors, hemostasis system, anthropometric data and adjuvant treatment. Optimal strategies for local advanced ECP are: 1) availability of very experienced thoracoabdominal surgeons because of complexity radical procedures; 2) aggressive en block surgery and adequate lymph node dissection for completeness; 3) precise prediction; 4) AT for ECP with unfavorable prognosis. Neural Networks: Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100%; n=119 Rank Sensitivity Phase Transition N0---N12 1 701 Eosinophils/Cancer Cells 2 491 Stick Neutrophils/Cancer Cells 3 269 Healthy Cells/Cancer Cells 4 176 Erythrocytes/Cancer Cells 5 175 Monocytes/Cancer Cells 6 151 Lymphocytes/Cancer Cells 7 124 Thrombocytes/Cancer Cells 8 100 Segmented Neutrophils/Cancer Cells 9 30 Leucocytes/Cancer Cells 10 24 Cox Proportional Hazards Results, ECPT4N0-2M0, n=153 Parameter Estimate Standard Error Chi2 P value Leucocytes -14.7695 3.568331 17.13163 0.000035 Monocytes (%) 0.9933 0.194297 26.13352 0.000000 ESS -0.0462 0.016035 8.29704 0.003971 Prothrombin Index 0.0745 0.016092 21.43087 0.000004 Eosinophils (abs) 24.0232 5.699437 17.76637 0.000025 Stick Neutrophils (abs) 11.5798 2.880807 16.15746 0.000058 Segmented Neutrophils (abs) 14.1418 3.858441 13.43337 0.000247 Lymphocytes (abs) 18.2601 4.034686 20.48277 0.000006 Phase Transition N0---N12 1.7942 0.350778 26.16159 0.000000 Age 0.0607 0.014796 16.81244 0.000041 Histology -0.9610 0.299217 10.31426 0.001320 Tumor Growth -0.7728 0.333794 5.36023 0.020601 Stick Neutrophils/Cancer Cells -10.4603 3.448870 9.19888 0.002422 Monocytes/Cancer Cells -11.4366 4.369661 6.85007 0.008864 Esophageal/Cardioesophageal Cancer 1.1047 0.305000 13.11926 0.000292 Eosinophils (%) -0.8866 0.224724 15.56375 0.000080 Segmented Neutrophils/Cancer Cells 1.2604 0.487956 6.67204 0.009794 Lymphocytes (tot) -2.7854 0.649292 18.40364 0.000018 Segmented Neutrophils (tot) -2.0776 0.573809 13.10942 0.000294 Leucocytes (tot) 2.1281 0.517175 16.93226 0.000039 Adjuvant Chemoimmunotherapy -1.4382 0.359631 15.99294 0.000064 G1-3 0.4878 0.167933 8.43792 0.003675 Protein 0.0438 0.019390 5.11383 0.023736 Healthy Cells/Cancer Cells 0.4984 0.231522 4.63402 0.031344 Erythrocytes/Cancer Cells -1.4656 0.604416 5.87966 0.015317 Thrombocytes/Cancer Cells -0.0114 0.005583 4.17846 0.040941 Eosinophils/Cancer Cells -10.6284 4.948386 4.61329 0.031725 Bootstrap Simulation: Number of Samples=3333 Rank Kendall Tau P< Hemorrhage Time 1 -0.171 0.05 Blood Chlorides 2 0.171 0.05 Esophageal/Cardioesophageal Cancer 3 -0.151 0.05 Prothrombin Index 4 -0.146 0.05 Phase Transition N0---N12 5 -0.144 0.05 Protein 6 -0.142 0.05 Survival Function 5-Year Survival=38.9%; 10-Year Survival=26.8%; 20-Year Survival=19.8%; n=153; T4N0-2M0 Complete Censored -5 0 5 10 15 20 25 30 35 Years after Combined Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of ECP with N0=52.8%; 5-Year Survival of ECP with N1-2=29.2%; P=0.00072 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 Years after Combined Esophagogastrectomies -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival after AT=51.1%; 5-Year Survival after Surgery=33.9%; P=0.007 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Combined Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving only Surgery=99 AT=54 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of ECP=58.3%; 5-Year Survival of CECP=29.4%; P=0.00007 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Combined Esophagogastrectomies -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving ECP=58 CECP=105